AI drug development startup Pathos AI closes $237M investment

T2Covered by 1 source · first reported by SiliconANGLE at 23 Oct, 20:02 UTC

Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos’ investor roster includes big names such as AstraZeneca plc…